Clinical Trial Search

Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…

Primary: Concentration of Triamcinolone Acetonide in Synovial Fluid — 477.5; 923.7; 250.1; NA pg/mL

Primary: Most Efficacious and Tolerated Dosage of Decitabine (Period 1) — 0; 0; 0; 1 Incidents

Primary: Amyloid Deposition Obtained on a 18F-flutemetamol Brain Scan. — 1.65 ratio of flutemetamol absorbed — p=<0.05

Primary: Percentage of Participants Who Experience 1 or More Adverse Event (AE) — 82.9; 88.9 Percentage of Participants

Primary: Median Proportion Cells That Are Apoptotic in Epithelial Ovarian Tissue — .093; .115 proportion of total cells

Primary: Percentage of Subjects Who Have a Seroprotective Immune Response — 90.1; 70.5 Percentage of participants

Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 16 — 26.4; 54.8; 53.5 Percentage of Participants — p=< 0.001

Primary: Percent Continent — 0; 0; 6; 0 percentage of participants

Primary: Change in the Unified Dyskinesia Rating Scale (UDysRS) Total Score — -6.3; -20.7 units on a scale — p=<0.0001

Primary: < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L — 5 Participants

Primary: The Number of Days Survived Without a Fall Over the 1 Year Duration of the Study — 239; 249.67 Days survived without a fall.

Primary: Reduce Calf Muscle Atrophy — 859.8; 874.9; 1450.4; 1634.9 mm^2

Primary: Percent of Eligible Participants Who Provided Consent — 90 Participants

Primary: Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of…